Joel Katz
Las Vegas, NVNPI 1558475913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 349 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 24.5% of the total. Reporting peaked in 2021 at $2,419 and has fallen 97.1% since, to $69 in 2023.
Across 349 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- CSL Behring$841
- GSK$663
- Kaleo, Inc.$473
- Boehringer Ingelheim$330
- Takeda Pharmaceuticals U.S.A., Inc.$309
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$6,89596%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $1,759 |
| CSL Behring | 50 | $841 |
| GSK | 43 | $663 |
| Kaleo, Inc. | 22 | $473 |
| Boehringer Ingelheim | 23 | $330 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $309 |
| Sanofi | 16 | $298 |
| Optinose US, Inc. | 18 | $287 |
| Pfizer | 17 | $278 |
| Novartis | 9 | $245 |
| Shire North American Group Inc | 4 | $231 |
| Amgen | 12 | $229 |
| Octapharma USA, Inc. | 10 | $192 |
| Pharming Healthcare, Inc. | 6 | $177 |
| Covis Pharma GmbH | 9 | $138 |
| Biocryst US Sales Co., LLC | 6 | $115 |
| Incyte Corporation | 6 | $106 |
| AbbVie | 3 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Merck | 1 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| LEO Pharma Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $26 |
| Bio Products Laboratory USA, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $17 |
| Biocryst Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.